Sepsis Outcomes(败血症结果)研究综述
Sepsis Outcomes 败血症结果 - Background: We aimed to assess the effects of zinc sulfate supplementation on sepsis outcomes in neonates. [1] Presepsin can be used as an early biomarker of sepsis outcomes. [2] CFH elevation, a known consequence of clinical septic shock, adversely impacts sepsis outcomes through more than one mechanism and is a biologically plausible, non-antibiotic, non-cytokine target for therapeutic intervention. [3] Last, the data support CD52 as a prognostic biomarker and therapeutic target for sepsis as its expression dynamically increases in lymphocytes and correlates with improved sepsis outcomes. [4] Low-volume rural hospitals have worse sepsis outcomes, and emergency department (ED)-based telemedicine (tele-ED) has been one promising strategy for improving rural sepsis care. [5] BACKGROUND Previous studies have explored the relationship between socioeconomic status and sepsis outcomes OBJECTIVES: The purpose of this investigation is to determine if race, ethnicity, economic stability, neighborhood environment, and access to health care are predictive of mortality in patients with septic shock. [6] BACKGROUND: A 56 US hospital collaborative, Improving Pediatric Sepsis Outcomes, has developed variables, metrics and a data analysis plan to track quality improvement (QI)–based patient outcomes over time. [7] Conclusions While we saw a declining trend of young infant sepsis CFRs among high and upper middle income countries across the years, the increasing trend amongst lower middle and low income countries highlights a disparity in infant sepsis outcomes based on resource availability. [8] To estimate the impact of relative platelet reductions and absolute platelet counts on sepsis outcomes. [9] INTRODUCTION The impact of albumin resuscitation on sepsis outcomes is debated, particularly in the initial phase of resuscitation. [10] Aim: To determine the effect of the EASY (Early Attention to Sepsis in the Young) protocol on sepsis outcomes in children admitted into the children's emergency unit. [11] Introduction: To compare encounter estimates and demographics of pediatric patients (<18 years) meeting modified Improving Pediatric Sepsis Outcomes (IPSO) criteria for sepsis to cohorts obtained using other criteria for pediatric sepsis from administrative datasets. [12] OBJECTIVES To determine whether race is a major determinant of sepsis outcomes when controlling for socioeconomic factors. [13] Conclusions Lipoproteins predicted poor sepsis outcomes. [14] In this study, we applied both genetic and pharmacological approaches to evaluate whether Beclin-1 activation improves sepsis outcomes in a model of pneumonia-induced sepsis. [15] Purpose Evaluate if O-GlcNAc stimulation could improve sepsis outcomes in young. [16] We investigated the best timing for using the National Early Warning Score 2 (NEWS2) for predicting sepsis outcomes and whether combining the NEWS2 and the Sequential Organ Failure Assessment (SOFA) was applicable for mortality risk stratification in intensive care unit (ICU) patients with severe sepsis. [17] The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. [18] Machine learning-based clinical decision support tools for sepsis create opportunities to identify at-risk patients and initiate treatments earlier, an important step in improving sepsis outcomes. [19] MEASUREMENTS Changes in SEP-1-targeted processes, including antibiotic administration, lactate measurement, and fluid administration at 3 hours from sepsis onset; repeated lactate and vasopressor administration for hypotension within 6 hours of sepsis onset; and sepsis outcomes, including risk-adjusted intensive care unit (ICU) admission, in-hospital mortality, and home discharge among survivors. [20] A Chi-square test was carried out to observe the relationship between Vitamin D levels and sepsis outcomes, and a Mann-Whitney test was done to assess the significance between Vitamin D levels and length of hospital stay. [21] Objective Evaluate if O-GlcNAc stimulation could improve sepsis outcomes in young. [22] The Centers for Medicare & Medicaid Service (CMS) Severe Sepsis and Septic Shock Bundle (SEP-1) is an evidence-based early management bundle focused on improving sepsis outcomes. [23] The combination of BCL-xL and SNAP-II was more sensitive and specific than the BCL-xL to predict neonatal sepsis outcomes. [24] Vitamin D levels have inverse correlation with sepsis outcomes and obesity may aggravate the severity of the diseases. [25] METHODS We reviewed patient data from a pediatric sepsis outcomes dataset collected at two tertiary care pediatric hospital sites from January 2017-December 2018. [26] Long-term β-blocker users are known to have lower lactate concentrations and favorable sepsis outcomes. [27] Background: Since 2016, our hospital joined the Improving Pediatric Sepsis Outcomes (IPSO) initiative, a national effort to improve pediatric sepsis care by incorporating bundled standardized care into the Emergency Department, Inpatient and Pediatric Intensive Care Unit (PICU) settings. [28] Early prediction can improve the sepsis outcomes by prompt treatmentMethod: As part of the Physionet/Computing in Cardiology Challenge 2019, our team (FlyingBubble) proposed a Time-phAsed model for Sepsis Prediction (TASP). [29] Background: : Children’s Memorial Hermann Hospital (CMHH) joined the Improving Pediatric Sepsis Outcomes (IPSO) collaborative in July 2016 with successful data importation beginning Summer 2017. [30] Rationale: Population studies suggest improved sepsis outcomes with statins, but the results of randomized controlled trials in patients with sepsis and organ dysfunction in critical care settings have broadly been negative. [31] Accordingly, pharmacological interventions targeting this pathway have a potential to become an effective approach to control sepsis outcomes. [32] Conclusion In our efforts to improve sepsis outcomes, we focused on early recognition (Code Sepsis) and intervention (sepsis bundle). [33] Collectively, while our findings so far have shown the additional value or measuring cytokines andgenetic markers in sepsis outcomes in the local population, further largescare studies are needed in a heterogeneous septic population with arigorous analysis to know the significance of our findings. [34] Optimizing serum magnesium level near the upper limit of the normal range may improve severe sepsis outcomes. [35] Objectives To evaluate O-GlcNAc level from birth to adulthood in heart and evaluate if an increase in protein O-GlcNAcylation could improve sepsis outcomes in young. [36] Background The impact of antibiotic timing on sepsis outcomes remains controversial due to conflicting results from previous studies. [37] These inflammatory mediators can cause myocardial dysfunction, which may deteriorate sepsis outcomes. [38] These inflammatory mediators can cause myocardial dysfunction, which may deteriorate sepsis outcomes. [39] Background Rapid antibiotic administration is known to improve sepsis outcomes, however early diagnosis remains challenging due to complex presentation. [40] Objectives: To test the hypothesis that there are consequential and significant differences in sepsis outcomes that result from differences in a patient's clinical course leading up to sepsis hospitalization. [41] Early prediction of sepsis is critical for improving sepsis outcomes. [42] Although standardised care bundles improve sepsis outcomes in other populations, the benefits in cancer patients are unclear. [43] Therefore, reprogramming of these pro- and anti-inflammatory, as well as immune-response genes which are involved in acute systemic inflammation, is a therapy approach to prevent organ failure and to improve sepsis outcomes. [44] Prediction of LOS mortality is a critical step toward improvements in neonatal sepsis outcomes. [45] Early detection and antibiotic treatment of sepsis are critical for improving sepsis outcomes, where each hour of delayed treatment has been associated with roughly an 4-8% increase in mortality. [46] Conclusions: These data provide evidence that platelet activation mediates NLRP3 inflammasome activation in response to CLP, has a role in contributing to multi-organ injury in sepsis, and thus may be a novel therapeutic target to improve sepsis outcomes. [47] RationaleRacial disparities in sepsis outcomes have been previously reported. [48] However, there are limited data evaluating the impact of ASPs and RDT on sepsis outcomes in the setting of the new Sepsis-3 guidelines. [49] Early detection and antibiotic treatment of sepsis are critical for improving sepsis outcomes, where each hour of delayed treatment has been associated with roughly an 4-8% increase in mortality. [50]背景：我们旨在评估补充硫酸锌对新生儿脓毒症结局的影响。 [1] Presepsin 可用作脓毒症结果的早期生物标志物。 [2] CFH 升高是临床感染性休克的已知后果，它通过多种机制对脓毒症结果产生不利影响，并且是一种生物学上合理的、非抗生素、非细胞因子的治疗干预目标。 [3] 最后，数据支持 CD52 作为脓毒症的预后生物标志物和治疗靶点，因为它在淋巴细胞中的表达动态增加并与改善的脓毒症结果相关。 [4] 低容量的农村医院脓毒症预后较差，基于急诊科 (ED) 的远程医疗 (tele-ED) 一直是改善农村脓毒症护理的一种有前途的策略。 [5] 背景 以前的研究探讨了社会经济地位与脓毒症结局之间的关系 目标：本次调查的目的是确定种族、民族、经济稳定性、邻里环境和获得医疗保健是否可以预测脓毒性休克患者的死亡率。 [6] 背景：美国 56 家医院合作，改善儿科脓毒症结果，制定了变量、指标和数据分析计划，以随着时间的推移跟踪基于质量改进 (QI) 的患者结果。 [7] 结论 虽然我们看到多年来中高收入和中高收入国家的小婴儿脓毒症病死率呈下降趋势，但中低收入和低收入国家的增长趋势突出了基于资源可用性的婴儿脓毒症结局的差异。 [8] 估计相对血小板减少和绝对血小板计数对脓毒症结果的影响。 [9] 介绍 白蛋白复苏对脓毒症结局的影响存在争议，尤其是在复苏的初始阶段。 [10] 目的：确定 EASY（早期关注青少年脓毒症）方案对儿童急诊科住院儿童脓毒症结局的影响。 [11] 简介：比较符合改进的改善儿科脓毒症结果 (IPSO) 脓毒症标准的儿科患者（<18 岁）的遭遇估计和人口统计数据与使用其他儿科脓毒症标准从管理数据集中获得的队列。 [12] 目标 在控制社会经济因素时，确定种族是否是败血症结果的主要决定因素。 [13] 结论 脂蛋白预测败血症预后不良。 [14] 在这项研究中，我们应用遗传和药理学方法来评估 Beclin-1 激活是否能改善肺炎诱导脓毒症模型中的脓毒症结果。 [15] 目的 评估 O-GlcNAc 刺激是否可以改善年轻人的败血症结果。 [16] 我们调查了使用国家早期预警评分 2 (NEWS2) 预测脓毒症结果的最佳时机，以及将 NEWS2 和序贯器官衰竭评估 (SOFA) 结合是否适用于重症监护病房 (ICU) 重症患者的死亡风险分层败血症。 [17] 本研究的目的是评估肾素血管紧张素醛固酮系统 (RAAS) 抑制对脓毒症结局的保护作用。 [18] 基于机器学习的脓毒症临床决策支持工具为识别高危患者和更早开始治疗创造了机会，这是改善脓毒症结果的重要一步。 [19] 测量 SEP-1 靶向过程的变化，包括抗生素给药、乳酸测量和脓毒症发作后 3 小时的液体给药；在脓毒症发作后 6 小时内重复使用乳酸和血管加压药治疗低血压；和脓毒症结果，包括风险调整后的重症监护病房 (ICU) 入院、住院死亡率和幸存者出院。 [20] 进行卡方检验以观察维生素 D 水平与败血症结果之间的关系，并进行 Mann-Whitney 检验以评估维生素 D 水平与住院时间之间的显着性。 [21] 目的评估 O-GlcNAc 刺激是否可以改善年轻人的脓毒症结局。 [22] 医疗保险和医疗补助服务中心 (CMS) 严重脓毒症和感染性休克捆绑包 (SEP-1) 是一个基于证据的早期管理捆绑包，专注于改善脓毒症结果。 [23] BCL-xL 和 SNAP-II 的组合在预测新生儿败血症结果方面比 BCL-xL 更敏感和特异。 [24] 维生素 D 水平与败血症结果呈负相关，肥胖可能会加重疾病的严重程度。 [25] 方法 我们审查了从 2017 年 1 月至 2018 年 12 月在两个三级保健儿科医院收集的儿科败血症结果数据集的患者数据。 [26] 众所周知，长期使用 β 受体阻滞剂的人乳酸浓度较低，脓毒症预后良好。 [27] 背景：自 2016 年以来，我院加入了改善儿科脓毒症结局 (IPSO) 倡议，这是一项全国性的努力，通过将捆绑式标准化护理纳入急诊科、住院部和儿科重症监护室 (PICU) 设置来改善儿科脓毒症护理。 [28] nan [29] nan [30] nan [31] nan [32] nan [33] nan [34] nan [35] nan [36] nan [37] nan [38] nan [39] nan [40] nan [41] nan [42] nan [43] nan [44] nan [45] nan [46] nan [47] nan [48] nan [49] nan [50]
Improve Sepsis Outcomes
In this study, we applied both genetic and pharmacological approaches to evaluate whether Beclin-1 activation improves sepsis outcomes in a model of pneumonia-induced sepsis. [1] Purpose Evaluate if O-GlcNAc stimulation could improve sepsis outcomes in young. [2] Objective Evaluate if O-GlcNAc stimulation could improve sepsis outcomes in young. [3] Conclusion In our efforts to improve sepsis outcomes, we focused on early recognition (Code Sepsis) and intervention (sepsis bundle). [4] Objectives To evaluate O-GlcNAc level from birth to adulthood in heart and evaluate if an increase in protein O-GlcNAcylation could improve sepsis outcomes in young. [5] Background Rapid antibiotic administration is known to improve sepsis outcomes, however early diagnosis remains challenging due to complex presentation. [6] Although standardised care bundles improve sepsis outcomes in other populations, the benefits in cancer patients are unclear. [7] Therefore, reprogramming of these pro- and anti-inflammatory, as well as immune-response genes which are involved in acute systemic inflammation, is a therapy approach to prevent organ failure and to improve sepsis outcomes. [8] Conclusions: These data provide evidence that platelet activation mediates NLRP3 inflammasome activation in response to CLP, has a role in contributing to multi-organ injury in sepsis, and thus may be a novel therapeutic target to improve sepsis outcomes. [9] , hyperto hypo-immunity, and therefore, it is acknowledged that the simple suppression/inhibition of hyper-immunity does not improve sepsis outcomes [10]. [10]在这项研究中，我们应用遗传和药理学方法来评估 Beclin-1 激活是否能改善肺炎诱导脓毒症模型中的脓毒症结果。 [1] 目的 评估 O-GlcNAc 刺激是否可以改善年轻人的败血症结果。 [2] 目的评估 O-GlcNAc 刺激是否可以改善年轻人的脓毒症结局。 [3] nan [4] nan [5] nan [6] nan [7] nan [8] nan [9] nan [10]
Improving Sepsis Outcomes
Machine learning-based clinical decision support tools for sepsis create opportunities to identify at-risk patients and initiate treatments earlier, an important step in improving sepsis outcomes. [1] The Centers for Medicare & Medicaid Service (CMS) Severe Sepsis and Septic Shock Bundle (SEP-1) is an evidence-based early management bundle focused on improving sepsis outcomes. [2] Early prediction of sepsis is critical for improving sepsis outcomes. [3] Early detection and antibiotic treatment of sepsis are critical for improving sepsis outcomes, where each hour of delayed treatment has been associated with roughly an 4-8% increase in mortality. [4] Early detection and antibiotic treatment of sepsis are critical for improving sepsis outcomes, where each hour of delayed treatment has been associated with roughly an 4-8% increase in mortality. [5] Here, we show that mice with an impaired metabolic response, due to deficiency of the nuclear receptor PPARα in the liver, exhibit enhanced mortality upon bacterial infection despite a similar inflammatory response, suggesting that metabolic interventions may be a viable strategy for improving sepsis outcomes. [6]基于机器学习的脓毒症临床决策支持工具为识别高危患者和更早开始治疗创造了机会，这是改善脓毒症结果的重要一步。 [1] 医疗保险和医疗补助服务中心 (CMS) 严重脓毒症和感染性休克捆绑包 (SEP-1) 是一个基于证据的早期管理捆绑包，专注于改善脓毒症结果。 [2] nan [3] nan [4] nan [5] nan [6]
Pediatric Sepsis Outcomes
BACKGROUND: A 56 US hospital collaborative, Improving Pediatric Sepsis Outcomes, has developed variables, metrics and a data analysis plan to track quality improvement (QI)–based patient outcomes over time. [1] Introduction: To compare encounter estimates and demographics of pediatric patients (<18 years) meeting modified Improving Pediatric Sepsis Outcomes (IPSO) criteria for sepsis to cohorts obtained using other criteria for pediatric sepsis from administrative datasets. [2] METHODS We reviewed patient data from a pediatric sepsis outcomes dataset collected at two tertiary care pediatric hospital sites from January 2017-December 2018. [3] Background: Since 2016, our hospital joined the Improving Pediatric Sepsis Outcomes (IPSO) initiative, a national effort to improve pediatric sepsis care by incorporating bundled standardized care into the Emergency Department, Inpatient and Pediatric Intensive Care Unit (PICU) settings. [4] Background: : Children’s Memorial Hermann Hospital (CMHH) joined the Improving Pediatric Sepsis Outcomes (IPSO) collaborative in July 2016 with successful data importation beginning Summer 2017. [5]背景：美国 56 家医院合作，改善儿科脓毒症结果，制定了变量、指标和数据分析计划，以随着时间的推移跟踪基于质量改进 (QI) 的患者结果。 [1] 简介：比较符合改进的改善儿科脓毒症结果 (IPSO) 脓毒症标准的儿科患者（<18 岁）的遭遇估计和人口统计数据与使用其他儿科脓毒症标准从管理数据集中获得的队列。 [2] 方法 我们审查了从 2017 年 1 月至 2018 年 12 月在两个三级保健儿科医院收集的儿科败血症结果数据集的患者数据。 [3] 背景：自 2016 年以来，我院加入了改善儿科脓毒症结局 (IPSO) 倡议，这是一项全国性的努力，通过将捆绑式标准化护理纳入急诊科、住院部和儿科重症监护室 (PICU) 设置来改善儿科脓毒症护理。 [4] nan [5]
Improved Sepsis Outcomes
Last, the data support CD52 as a prognostic biomarker and therapeutic target for sepsis as its expression dynamically increases in lymphocytes and correlates with improved sepsis outcomes. [1] Rationale: Population studies suggest improved sepsis outcomes with statins, but the results of randomized controlled trials in patients with sepsis and organ dysfunction in critical care settings have broadly been negative. [2]最后，数据支持 CD52 作为脓毒症的预后生物标志物和治疗靶点，因为它在淋巴细胞中的表达动态增加并与改善的脓毒症结果相关。 [1] nan [2]
Deteriorate Sepsis Outcomes
These inflammatory mediators can cause myocardial dysfunction, which may deteriorate sepsis outcomes. [1] These inflammatory mediators can cause myocardial dysfunction, which may deteriorate sepsis outcomes. [2]Neonatal Sepsis Outcomes
The combination of BCL-xL and SNAP-II was more sensitive and specific than the BCL-xL to predict neonatal sepsis outcomes. [1] Prediction of LOS mortality is a critical step toward improvements in neonatal sepsis outcomes. [2]BCL-xL 和 SNAP-II 的组合在预测新生儿败血症结果方面比 BCL-xL 更敏感和特异。 [1] nan [2]